{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05269823",
            "orgStudyIdInfo": {
                "id": "OPH-2022-30605"
            },
            "organization": {
                "fullName": "University of Minnesota",
                "class": "OTHER"
            },
            "briefTitle": "Topical Ice-therapy for Intravitreal Injections",
            "officialTitle": "Topical Ice-therapy for Pain Modulation During Intravitreal Injections: A Prospective Randomized Control Trial",
            "therapeuticArea": [
                "Other"
            ],
            "study": "topical-ice-therapy-for-intravitreal-injections"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-04",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-04-01",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2025-04-01",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2025-08-01",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2022-01-16",
            "studyFirstSubmitQcDate": "2022-03-03",
            "studyFirstPostDateStruct": {
                "date": "2022-03-08",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-04-25",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-26",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "University of Minnesota",
                "class": "OTHER"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": false,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Purpose: To examine the difference in patient's pain experience in the setting of intravitreal anti-VEGF injections with pretreatment of topical ice-therapy compared with no-ice."
        },
        "conditionsModule": {
            "conditions": [
                "Anesthesia; Hypothermia",
                "Injection Site Irritation"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "NA"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "SUPPORTIVE_CARE",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 250,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Ice-therapy",
                    "type": "ACTIVE_COMPARATOR",
                    "description": "Ice therapy will be provided prior to the provision of the intravitreal injection",
                    "interventionNames": [
                        "Other: Ice-therapy"
                    ]
                },
                {
                    "label": "No Ice-therapy",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "No ice therapy will be provided prior to the provision of the intravitreal injection",
                    "interventionNames": [
                        "Other: No Ice-therapy"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "OTHER",
                    "name": "Ice-therapy",
                    "description": "Ice therapy will be provided prior to intravitreal injection provision",
                    "armGroupLabels": [
                        "Ice-therapy"
                    ]
                },
                {
                    "type": "OTHER",
                    "name": "No Ice-therapy",
                    "description": "No additional intervention (i.e.) ice therapy will be provided prior to intravitreal injection provision",
                    "armGroupLabels": [
                        "No Ice-therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Discomfort assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to discomfort, while a rating of ten signifies the maximum self-reported subjective rating attributed to discomfort.",
                    "timeFrame": "This will be assessed at five minutes after the conclusion of the intravitreal injection"
                },
                {
                    "measure": "Itching assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to itching, while a rating of ten signifies the maximum self-reported subjective rating attributed to itching.",
                    "timeFrame": "This will be assessed at five minutes after the conclusion of the intravitreal injection"
                },
                {
                    "measure": "Burning assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to burning, while a rating of ten signifies the maximum self-reported subjective rating attributed to burning.",
                    "timeFrame": "This will be assessed at five minutes after the conclusion of the intravitreal injection"
                },
                {
                    "measure": "Overall Pain assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to overall pain, while a rating of ten signifies the maximum self-reported subjective rating attributed to overall pain.",
                    "timeFrame": "This will be assessed at five minutes after the conclusion of the intravitreal injection"
                },
                {
                    "measure": "Overall Tolerability assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to overall tolerability, while a rating of ten signifies the maximum self-reported subjective rating attributed to overall tolerability.",
                    "timeFrame": "This will be assessed at five minutes after the conclusion of the intravitreal injection"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Discomfort assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to discomfort, while a rating of ten signifies the maximum self-reported subjective rating attributed to discomfort.",
                    "timeFrame": "This will be assessed at 24-hours after the conclusion of the intravitreal injection"
                },
                {
                    "measure": "Itching assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to itching, while a rating of ten signifies the maximum self-reported subjective rating attributed to itching.",
                    "timeFrame": "This will be assessed at 24-hours after the conclusion of the intravitreal injection"
                },
                {
                    "measure": "Burning assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to burning, while a rating of ten signifies the maximum self-reported subjective rating attributed to burning.",
                    "timeFrame": "This will be assessed at 24-hours after the conclusion of the intravitreal injection"
                },
                {
                    "measure": "Overall Pain assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to overall pain, while a rating of ten signifies the maximum self-reported subjective rating attributed to overall pain.",
                    "timeFrame": "This will be assessed at 24-hours after the conclusion of the intravitreal injection"
                },
                {
                    "measure": "Overall Tolerability assessed by the visual analog scale",
                    "description": "This primary outcome measure will be surveyed using a visual analog scale to quantify discomfort from a numerical level of one to ten. A self reported rating of one represents the lowest self-reported subjective rating attributed to overall tolerability, while a rating of ten signifies the maximum self-reported subjective rating attributed to overall tolerability.",
                    "timeFrame": "This will be assessed at 24-hours after the conclusion of the intravitreal injection"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* All patients aged 18 or older evaluated by a single retina specialist at the University of Minnesota Department of Ophthalmology with a clinical indication necessitating an anti-VEGF intravitreal injection\n\nExclusion Criteria:\n\n* N/A",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Jade Moon, MD",
                    "role": "CONTACT",
                    "email": "moon0278@umn.edu"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Jade Moon, MD",
                    "affiliation": "University of Minnesota",
                    "role": "PRINCIPAL_INVESTIGATOR"
                }
            ],
            "locations": [
                {
                    "facility": "University of Minnesota",
                    "status": "RECRUITING",
                    "city": "Minneapolis",
                    "state": "Minnesota",
                    "zip": "55455",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Jade Moon, M.D.",
                            "role": "CONTACT",
                            "email": "moon0278@umn.edu"
                        }
                    ],
                    "geoPoint": {
                        "lat": 44.97997,
                        "lon": -93.26384
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "UNDECIDED"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000007035",
                    "term": "Hypothermia"
                }
            ],
            "ancestors": [
                {
                    "id": "D000001832",
                    "term": "Body Temperature Changes"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M13066",
                    "name": "Pain",
                    "relevance": "LOW"
                },
                {
                    "id": "M10085",
                    "name": "Hypothermia",
                    "asFound": "Hypothermia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M5111",
                    "name": "Body Temperature Changes",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                }
            ]
        }
    },
    "hasResults": false
}